YSB (09885) surged over 4% in morning trading. As of press time, the stock was up 4.19% to HK$10.63, with a trading volume of HK$10.8058 million.

On the news front, YSB released its interim report for 2025 on August 20. In the first half of this year, the company achieved operating revenue of RMB 9.843 billion, representing an 11.7% year-on-year increase. The gross margin improved significantly from 10% to 11.2%. Net profit attributable to shareholders reached RMB 78.11 million, more than tripling compared to the same period last year. Operating cash flow maintained a positive net inflow of RMB 257 million, while cash and cash equivalents stood at RMB 3.551 billion.

Against the backdrop of widespread pressure in the pharmaceutical market this year, the company maintained double-digit revenue growth and exponential net profit growth, with significantly enhanced profitability and consistently healthy cash flow conditions.

In the first half of this year, YSB maintained steady development through its "platform + self-operated" dual-wheel business model, continuously strengthening its digital foundation and focusing on three key strategic initiatives: own-brand expansion, supply chain efficiency improvement, and primary healthcare market penetration, driving continuous optimization of its profit structure.

The continued expansion of the own-brand business has further enhanced the company's supply capacity and operational capabilities, achieving sustained growth in high-margin business segments and continuously improving the company's gross margin level. The report shows that own-brand transaction volume reached RMB 852 million, representing approximately 473.4% year-on-year growth.

Among these, the strategic flagship product Huoxiang Zhengqi Oral Liquid contributed 40% of sales to primary healthcare institution customers. The second major product, Pharmacist Le Changyanling Oral Liquid, covered over 30,000 independent pharmacies and primary healthcare institutions within two months.